RxDoctor Payments Data

James Lamon, MD

Internal Medicine · Moultrie, GANPI 1013019033

Payments from drug & device makers

$8,504in general payments, 2019–2025

Across 441 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Sekisui Diagnostics LLC$960
  • Amgen$882
  • AstraZeneca$877
  • Novo Nordisk$872
  • Bayer$546
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$451%
  • Food & beverage$7,22285%
  • Education$2773%
  • Gifts$96011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,504 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$179,810
Medicare patients
1,308
Services billed
3,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide574$686,784
FarxigaDapagliflozin Propanediol614$515,286
CreonLipase/Protease/Amylase109$316,205
JardianceEmpagliflozin301$302,233
EpclusaSofosbuvir/Velpatasvir11$276,258
EliquisApixaban315$242,148
OzempicSemaglutide216$224,260
Trelegy ElliptaFluticasone/Umeclidin/Vilanter265$211,444
LinzessLinaclotide188$144,916
BiktarvyBictegrav/Emtricit/Tenofov Ala32$130,517
Tresiba Flextouch U-200Insulin Degludec130$118,978
TradjentaLinagliptin134$110,101
TrulicityDulaglutide89$105,076
KerendiaFinerenone109$93,296
XareltoRivaroxaban129$93,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$144$791,860663 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$877$601,375733 claims
AbbVieCreon, Linzess, Vraylar$373$533,295346 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$12$431,313474 claims
GileadEpclusa, Biktarvy$67$406,77443 claims
Novo NordiskOzempic, Rybelsus$872$282,812249 claims
PfizerEliquis$215$242,148315 claims
GSKTrelegy Ellipta$1,195$211,444265 claims
Johnson & JohnsonXarelto, Invokana$208$109,675144 claims
MerckJanuvia, Lagevrio (Eua)$85$99,500114 claims
BayerKerendia$546$93,296109 claims
Astellas Pharma US IncMyrbetriq$115$63,84181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Moultrie

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →